# Adeia Inc.: financial statements, quarterly

ADEA · Nasdaq · CIK 1803696 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/adea.md) · [Financials](/companies/adea/financials.md) · [Filings](/companies/adea/filings.md) · [Insiders](/companies/adea/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/adea/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [101](/filings/0000950170-24-125099.md) | [86.9 d](/filings/0001193125-26-076549.md) | [83.4](/filings/0000950170-25-064434.md) | [87.4](/filings/0001193125-25-175417.md) | [86.1](/filings/0001193125-25-269642.md) | [119 d](/filings/0001193125-26-076549.md) | [87.7](/filings/0001193125-26-208924.md) | [85.7](/filings/0001193125-26-335038.md) | [87.3](/filings/0001193125-25-269642.md) | [183 d](/filings/0001193125-26-076549.md) | [105](/filings/0001193125-26-208924.md) | [96.1](/filings/0001193125-26-335038.md) |
| Research and development | $m | [13.8](/filings/0000950170-24-125099.md) | [14.4 d](/filings/0001193125-26-076549.md) | [13.9](/filings/0000950170-25-064434.md) | [14.8](/filings/0001193125-25-175417.md) | [14.8](/filings/0001193125-25-269642.md) | [16.0 d](/filings/0001193125-26-076549.md) | [16.5](/filings/0001193125-26-208924.md) | [15.9](/filings/0001193125-26-335038.md) | [16.0](/filings/0001193125-25-269642.md) | [19.2 d](/filings/0001193125-26-076549.md) | [18.2](/filings/0001193125-26-208924.md) | [18.3](/filings/0001193125-26-335038.md) |
| Selling, general and administrative | $m | [21.9](/filings/0000950170-24-125099.md) | [24.0 d](/filings/0001193125-26-076549.md) | [24.0](/filings/0000950170-25-064434.md) | [24.6](/filings/0001193125-25-175417.md) | [26.9](/filings/0001193125-25-269642.md) | [27.9 d](/filings/0001193125-26-076549.md) | [28.4](/filings/0001193125-26-208924.md) | [32.1](/filings/0001193125-26-335038.md) | [24.9](/filings/0001193125-25-269642.md) | [34.1 d](/filings/0001193125-26-076549.md) | [29.8](/filings/0001193125-26-208924.md) | [31.0](/filings/0001193125-26-335038.md) |
| Operating income | $m | [40.1](/filings/0000950170-24-125099.md) | [23.3 d](/filings/0001193125-26-076549.md) | [19.4](/filings/0000950170-25-064434.md) | [23.6](/filings/0001193125-25-175417.md) | [28.1](/filings/0001193125-25-269642.md) | [57.5 d](/filings/0001193125-26-076549.md) | [22.8](/filings/0001193125-26-208924.md) | [16.4](/filings/0001193125-26-335038.md) | [27.0](/filings/0001193125-25-269642.md) | [109 d](/filings/0001193125-26-076549.md) | [34.8](/filings/0001193125-26-208924.md) | [25.4](/filings/0001193125-26-335038.md) |
| Income tax | $m | [1.7](/filings/0000950170-24-125099.md) | [(3.3) d](/filings/0001193125-26-076549.md) | [5.7](/filings/0000950170-25-064434.md) | [2.9](/filings/0001193125-25-175417.md) | [(2.5)](/filings/0001193125-25-269642.md) | [10.5 d](/filings/0001193125-26-076549.md) | [2.1](/filings/0001193125-26-208924.md) | [(9.1)](/filings/0001193125-26-335038.md) | [9.6](/filings/0001193125-25-269642.md) | [27.3 d](/filings/0001193125-26-076549.md) | [5.2](/filings/0001193125-26-208924.md) | [1.6](/filings/0001193125-26-335038.md) |
| Net income | $m | [24.2](/filings/0000950170-24-125099.md) | [12.7 d](/filings/0001193125-26-076549.md) | [0.9](/filings/0000950170-25-064434.md) | [8.4](/filings/0001193125-25-175417.md) | [19.3](/filings/0001193125-25-269642.md) | [36.0 d](/filings/0001193125-26-076549.md) | [11.8](/filings/0001193125-26-208924.md) | [16.7](/filings/0001193125-26-335038.md) | [8.8](/filings/0001193125-25-269642.md) | [73.7 d](/filings/0001193125-26-076549.md) | [22.8](/filings/0001193125-26-208924.md) | [17.4](/filings/0001193125-26-335038.md) |
| Diluted EPS | $ per share | [0.21](/filings/0000950170-24-125099.md) | not reported | [0.01](/filings/0000950170-25-064434.md) | [0.07](/filings/0001193125-25-175417.md) | [0.17](/filings/0001193125-25-269642.md) | not reported | [0.10](/filings/0001193125-26-208924.md) | [0.15](/filings/0001193125-26-335038.md) | [0.08](/filings/0001193125-25-269642.md) | not reported | [0.20](/filings/0001193125-26-208924.md) | [0.15](/filings/0001193125-26-335038.md) |
| Basic EPS | $ per share | [0.23](/filings/0000950170-24-125099.md) | not reported | [0.01](/filings/0000950170-25-064434.md) | [0.08](/filings/0001193125-25-175417.md) | [0.18](/filings/0001193125-25-269642.md) | not reported | [0.11](/filings/0001193125-26-208924.md) | [0.15](/filings/0001193125-26-335038.md) | [0.08](/filings/0001193125-25-269642.md) | not reported | [0.21](/filings/0001193125-26-208924.md) | [0.16](/filings/0001193125-26-335038.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [51.9](/filings/0000950170-23-059393.md) | [54.6](/filings/0000950170-25-023148.md) | [58.0](/filings/0000950170-24-055618.md) | [66.5](/filings/0000950170-24-092744.md) | [60.7](/filings/0000950170-24-125099.md) | [78.8](/filings/0001193125-26-076549.md) | [84.2](/filings/0000950170-25-064434.md) | [84.2](/filings/0001193125-25-175417.md) | [56.1](/filings/0001193125-25-269642.md) | [73.1](/filings/0001193125-26-335038.md) | [53.3](/filings/0001193125-26-208924.md) | [72.8](/filings/0001193125-26-335038.md) |
| Current assets | $m | [220](/filings/0000950170-23-059393.md) | [206](/filings/0000950170-25-023148.md) | [206](/filings/0000950170-24-055618.md) | [219](/filings/0000950170-24-092744.md) | [245](/filings/0000950170-24-125099.md) | [258](/filings/0001193125-26-076549.md) | [263](/filings/0000950170-25-064434.md) | [267](/filings/0001193125-25-175417.md) | [281](/filings/0001193125-25-269642.md) | [304](/filings/0001193125-26-335038.md) | [281](/filings/0001193125-26-208924.md) | [295](/filings/0001193125-26-335038.md) |
| Total assets | $m | [1,124](/filings/0000950170-23-059393.md) | [1,106](/filings/0000950170-25-023148.md) | [1,079](/filings/0000950170-24-055618.md) | [1,069](/filings/0000950170-24-092744.md) | [1,083](/filings/0000950170-24-125099.md) | [1,098](/filings/0001193125-26-076549.md) | [1,087](/filings/0000950170-25-064434.md) | [1,083](/filings/0001193125-25-175417.md) | [1,069](/filings/0001193125-25-269642.md) | [1,039](/filings/0001193125-26-335038.md) | [1,002](/filings/0001193125-26-208924.md) | [1,013](/filings/0001193125-26-335038.md) |
| Current liabilities | $m | [81.9](/filings/0000950170-23-059393.md) | [102](/filings/0000950170-25-023148.md) | [92.6](/filings/0000950170-24-055618.md) | [73.2](/filings/0000950170-24-092744.md) | [71.5](/filings/0000950170-24-125099.md) | [73.1](/filings/0001193125-26-076549.md) | [89.7](/filings/0000950170-25-064434.md) | [86.5](/filings/0001193125-25-175417.md) | [75.3](/filings/0001193125-25-269642.md) | [79.8](/filings/0001193125-26-335038.md) | [81.7](/filings/0001193125-26-208924.md) | [90.9](/filings/0001193125-26-335038.md) |
| Total liabilities | $m | [780](/filings/0000950170-23-059393.md) | [749](/filings/0000950170-25-023148.md) | [729](/filings/0000950170-24-055618.md) | [710](/filings/0000950170-24-092744.md) | [705](/filings/0000950170-24-125099.md) | [701](/filings/0001193125-26-076549.md) | [698](/filings/0000950170-25-064434.md) | [680](/filings/0001193125-25-175417.md) | [655](/filings/0001193125-25-269642.md) | [559](/filings/0001193125-26-335038.md) | [536](/filings/0001193125-26-208924.md) | [536](/filings/0001193125-26-335038.md) |
| Long-term debt | $m | [577](/filings/0000950170-23-059393.md) | [520](/filings/0000950170-25-023148.md) | [509](/filings/0000950170-24-055618.md) | [511](/filings/0000950170-24-092744.md) | [500](/filings/0000950170-24-125099.md) | [454](/filings/0001193125-26-076549.md) | [438](/filings/0000950170-25-064434.md) | [428](/filings/0001193125-25-175417.md) | [418](/filings/0001193125-25-269642.md) | [397](/filings/0001193125-26-335038.md) | [370](/filings/0001193125-26-208924.md) | [365](/filings/0001193125-26-335038.md) |
| Current portion of debt | $m | [37.0](/filings/0000950170-23-059393.md) | [66.1](/filings/0000950170-25-023148.md) | [36.9](/filings/0000950170-24-055618.md) | [24.8](/filings/0000950170-24-092744.md) | [24.7](/filings/0000950170-24-125099.md) | [21.0](/filings/0001193125-26-076549.md) | [21.0](/filings/0000950170-25-064434.md) | [21.0](/filings/0001193125-25-175417.md) | [21.0](/filings/0001193125-25-269642.md) | [21.0](/filings/0001193125-26-335038.md) | [21.0](/filings/0001193125-26-208924.md) | [21.0](/filings/0001193125-26-335038.md) |
| Shareholders' equity | $m | [344](/filings/0000950170-23-059393.md) | [357](/filings/0000950170-25-023148.md) | [350](/filings/0000950170-24-055618.md) | [359](/filings/0000950170-24-092744.md) | [378](/filings/0000950170-24-125099.md) | [397](/filings/0001193125-26-076549.md) | [389](/filings/0000950170-25-064434.md) | [403](/filings/0001193125-25-175417.md) | [414](/filings/0001193125-25-269642.md) | [481](/filings/0001193125-26-335038.md) | [467](/filings/0001193125-26-208924.md) | [477](/filings/0001193125-26-335038.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [21.2 d](/filings/0000950170-24-125099.md) | [39.4 d](/filings/0001193125-26-076549.md) | [67.2](/filings/0000950170-25-064434.md) | [23.5 d](/filings/0001193125-25-175417.md) | [14.3 d](/filings/0001193125-25-269642.md) | [107 d](/filings/0001193125-26-076549.md) | [57.1](/filings/0001193125-26-208924.md) | [23.1 d](/filings/0001193125-26-335038.md) | [17.8 d](/filings/0001193125-25-269642.md) | [60.0 d](/filings/0001193125-26-076549.md) | [58.5](/filings/0001193125-26-208924.md) | [54.6 d](/filings/0001193125-26-335038.md) |
| Capital expenditure | $m | [0.4 d](/filings/0000950170-24-125099.md) | [1.9 d](/filings/0001193125-26-076549.md) | [0.8](/filings/0000950170-25-064434.md) | [0.4 d](/filings/0001193125-25-175417.md) | [0.1 d](/filings/0001193125-25-269642.md) | [0.5 d](/filings/0001193125-26-076549.md) | [0.2](/filings/0001193125-26-208924.md) | [0.2 d](/filings/0001193125-26-335038.md) | [0.8 d](/filings/0001193125-25-269642.md) | [0.6 d](/filings/0001193125-26-076549.md) | [0.4](/filings/0001193125-26-208924.md) | [0.6 d](/filings/0001193125-26-335038.md) |
| Dividends paid | $m | [5.3 d](/filings/0000950170-24-125099.md) | [5.4 d](/filings/0001193125-26-076549.md) | [5.4](/filings/0000950170-25-064434.md) | [5.4 d](/filings/0001193125-25-175417.md) | [5.5 d](/filings/0001193125-25-269642.md) | [5.5 d](/filings/0001193125-26-076549.md) | [5.4](/filings/0001193125-26-208924.md) | [5.4 d](/filings/0001193125-26-335038.md) | [5.5 d](/filings/0001193125-25-269642.md) | [5.4 d](/filings/0001193125-26-076549.md) | [5.5](/filings/0001193125-26-208924.md) | [5.5 d](/filings/0001193125-26-335038.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-23-059393.md) | [0.0 d](/filings/0001193125-26-076549.md) | [0.0](/filings/0000950170-25-064434.md) | [0.0 d](/filings/0001193125-25-175417.md) | [0.0 d](/filings/0001193125-25-269642.md) | [18.7 d](/filings/0001193125-26-076549.md) | [11.3](/filings/0001193125-26-208924.md) | [0.0 d](/filings/0001193125-26-335038.md) | [0.0 d](/filings/0001193125-25-269642.md) | [10.0 d](/filings/0001193125-26-076549.md) | [10.0](/filings/0001193125-26-208924.md) | [10.0 d](/filings/0001193125-26-335038.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [113](/filings/0000950170-25-023148.md) | [113](/filings/0000950170-24-055618.md) | [113](/filings/0000950170-24-092744.md) | [113](/filings/0000950170-24-125099.md) | [113](/filings/0000950170-25-064434.md) | [113](/filings/0001193125-25-175417.md) | [113](/filings/0001193125-25-269642.md) | [113](/filings/0001193125-26-208924.md) | [112](/filings/0001193125-26-335038.md) | [113](/filings/0001193125-25-269642.md) | [114](/filings/0001193125-26-208924.md) | [114](/filings/0001193125-26-335038.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 110,280,150 at 2026-07-24, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335038.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.